The Cholesterol Lowering Atherosclerosis PTCA Trial (CLAPT) is a prospective, randomized trial with blinded angiographic end-points to assess the effect of 2-year's treatment with lovastatin initiated 4 weeks prior to PTCA, compared to usual care on non-dilated coronary segments and on dilated coronary lesions in male patients with total cholesterol between 200 and 300 mg . dl 1 who underwent elective PTCA.
1
. Total-and LDLcholesterol decreased by 21% and 29% in the special care group and by 7% and 11% in the usual care patients. After 2 years, the mean segment diameter of non-dilated segments decreased by 0·03 mm in the usual care group and 0·004 mm in the special care group (P=0·27). The decrease in the mean segment diameter of dilated lesions was 0·17 mm (usual care) and 0·06 mm (special care) (P=0·04) after 4 months; 0·16 mm (usual care) and 0·002 mm (special care) after 24 months, respectively (P=0·05). In both groups, the mean segment diameter of dilated lesions increased between 4 and 24 months after PTCA compared to a decrease in mean segment diameter of non-dilated segments (P<0·05). Restenosis (>50% diameter stenosis at follow-up) occurred in 28·4% of usual care and 22·2% of special care patients (P=0·17).
Introduction
In patients with hypercholesterolaemia and angiographically documented coronary artery disease not requiring PTCA (percutaneous transluminal coronary angioplasty), intense lipid lowering treatment reduces progression of coronary atheroclerosis, as assessed either by visual estimation or quantitative analysis of serial coronary angiograms [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Of these trials, only the Regression Growth Evaluation Statin Study (REGRESS) included patients with PTCA as the primary treatment in one of three treatment arms, but the published results have been restricted to non-dilated segments [14] . To date, limited data are available on the long-term benefit of lipid-lowering treatment on either non-dilated or dilated lesions in the same patients with moderately elevated serum cholesterol levels who undergo PTCA.
The high restenosis rate remains a limiting factor of PTCA [15] . Since lovastatin has been shown to have an antiproliferative effect on smooth muscle cells with reduction of restenosis rate after experimental balloon injury [16, 17] , it might prevent restenosis after PTCA in humans. Two clinical restenosis trials with lovastatin have shown inconsistent results, with reduction of restenosis rate in one study [18] and no effect in the other [19] . The Cholesterol Lowering Atherosclerosis PTCA Trial (CLAPT) was designed in 1989. At this time only a few angiographic trials studied the effect of lovastatin initiated 4 weeks prior to PTCA on progression and regression of non-dilated segments and on dilated and non-dilated lesions using quantitative coronary angiography.
Methods

Study design and enrollment
CLAPT is a prospective, randomized, four-centre trial with blinded angiographic end-points to assess the effect of 2 years non-blinded treatment with lovastatin, an HMG-CoA reductase inhibitor initiated 4 weeks prior to PTCA, compared to usual care, on non-dilated coronary segments and on dilated coronary lesions in male patients with total cholesterol between 200 and 300 mg . dl 1 who underwent elective PTCA. In each of the four clinical centres, consecutive men aged 18 to 70 years scheduled for elective PTCA were screened for study inclusion and exclusion criteria. The inclusion and exclusion criteria are summarized in Table 1 . Between June 1991 and September 1995, 9300 consecutive male patients scheduled for PTCA were screened to identify 350 patients who met the study entry criteria. The main exclusion criteria were rePTCA, age, previous CABG, (coronary artery bypass grafting), unstable angina and myocardial infarction within 4 weeks prior to randomization. Two hundred and twenty-six of them gave informed written consent and were randomized 4 weeks prior to PTCA to diet or diet combined with lovastatin. Lovastatin treatment was started 4 weeks prior to PTCA to assess whether aggressive lipid-lowering therapy would decrease the restenosis rate after PTCA.
Treatment
Before randomization, all patients received diet counselling by a dietician or the local investigator with the goal of achieving adequate caloric intake and composition of the diet according to phase I of the AHA (American Heart Association) recommendations [20] . At follow-up visits, dietary advice was repeated either by the dietician or the investigator according to the practice of the centre. Patients randomized to diet combined with lovastatin (special care group) started with 20 mg . day 1 lovastatin 4 weeks prior to PTCA. The dosage was increased in 20 mg steps to a maximum dose of 80 mg . day 1 in patients whose LDL-cholesterol levels exceeded 120 mg . dl 1 at follow-up visits. In patients whose LDL-cholesterol decreased below 70 mg . dl 
Lipid measurements
Serum concentrations of triglycerides and cholesterol were quantified by enzymatic methods using an autoanalyser (Hitachi/Boehringer, Mannheim, Germany). HDL-cholesterol was measured after precipitation of apoB-containing lipoproteins with phosphotungstic acid/MgC12 (Boehringer Mannheim, Germany) [21] . Measurements of these parameters were controlled by the International Lipid Standardization Program which is organized by the Centers of Disease Control (Atlanta, GA, U.S.A.). Inter-assay imprecision was less than 3% for cholesterol, less than 4% for triglycerides, and less than 6% for HDL-cholesterol. LDL-cholesterol was calculated using the Friedewald formula when triglycerides were below 400 mg . dl 1 [22] . Concentrations of apoA-I and apoB were determined with a modified commercially available turbidimetric assay (Boehringer Mannheim, Germany) [23] . Lp(a) was quantified by enzyme immunoassay (Vienna, Austria).
All lipid measurements, except for the initial screening tests necessary for recruitment, were performed in the central laboratory in Mü nster. However in one centre (Mü nster), the initial tests were also performed in the central laboratory. In two centres (Aachen and Berlin), the local screening results were verified in the central laboratory before the patient was definitely included in the study. The fourth centre (Bad Oeynhausen) performed a method comparison on 50 samples to measure cholesterol, triglycerides, and HDL-cholesterol. Since results were almost identical, patient recruitment at this centre was based on local measurements. For follow-up, serum samples were collected and kept frozen at 70 C. The samples were shipped frozen to the central laboratory where the measurements were performed. To minimize imprecision, apolipoproteins and Lp(a) were measured within one series after each patient had completed the study protocol.
Follow-up visits
The baseline coronary angiogram with PTCA were performed about 4 weeks after randomization. All patients were rehospitalized 4 to 6 months after PTCA for a first follow-up coronary angiogram and 24 months after PTCA for the second, final follow-up coronary angiogram. Special care patients were followed in outpatient clinics 8, 12 and 18 months after PTCA. Usual care patients were referred to the care of their general physicians and were interviewed by telephone 8, 12 and 18 months after PTCA using the same questionnaire as in the special care group. During hospitalization in both groups, fasting blood samples were taken for lipid analysis. In the special care group, during outpatient clinic visits blood chemistry and haematology analyses were performed to monitor safety. A history was taken using a computer-based questionnaire. Questions included a grading of the severity of angina pectoris according to the criteria of the Canadian Cardiovascular Society and a physical examination worksheet was completed. A 12-lead ECG at rest and exercise were obtained according to a standardized protocol.
Critical events
All critical events or adverse effects were documented and categorized following predetermined standardized definitions. Myocardial infarction (fatal and non-fatal) was defined as typical angina of >30 min duration, a doubling of serum creatine kinase and/or transaminases, new ischaemic ST-T wave changes or new abnormal Q waves of >0·03 s duration, or loss of R-waves on the ECG. During follow-up, rePTCA was classified as a second dilatation of the primary dilated lesion; PTCA in a segment different from the primary dilated lesion was classified as a second PTCA. The clinically based decision for a rePTCA, second PTCA or CABG was categorized as being due to (1) restenosis, (2) angina pectoris, (3) myocardial infarction or (4) progression. Other critical events, for example neurological disorders, were not predefined but carefully documented.
Quantitative coronary angiography
Coronary angiograms All coronary angiograms were performed following standard requirements for quantitative analysis [24, 25] . In brief, the lesion to be dilated was filmed in orthogonal views that best demonstrated the lesion, avoiding foreshortening as much as possible. To reduce pincushion distortion, the lesion was placed in the centre of the image. The PTCA followed a standardized protocol, with intravenous application of 10 000-15 000 IE heparin and 1 g acetylsalicylic acid before PTCA.
For non-dilated segments, different projections (minimum of three for the right coronary artery and five for the left coronary artery) of the coronary arteries were recorded to allow further analysis of non-foreshortened segments. To reduce the vasomuscular tone of the coronary arteries, all patients received 0·2 mg intracoronary nitroglycerin. All initial projections were recorded and reproduced in follow-up coronary angiograms using the same angiographic unit.
Quantitative coronary angiographic analysis
The identity of the cinefilms of each patient was blinded by an independent technician at the external statistical centre after the final coronary angiogram. A randomly allocated number enabled the cinefilms to be identified as a baseline film with PTCA performed, or a followup, or an additional cinefilm. Patient identification,
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treatment group and sequence of follow-up films were blinded. All quantitative coronary angiography analyses were done in the quantitative coronary angiography reference laboratory in Mü nster, Germany. The triplet of CLAPT coronary angiograms were reviewed by a cardiologist and a trained technician. For each dilated lesion and for non-dilated segments the PTCA cinefilm was used to identify the best visualization of dilated lesions or non-dilated segments from the end-diastolic frame with minimum foreshortening, good contrast filling, and no overlapping structures. Identical matching frames of dilated lesions and non-dilated segments in the two follow-up cinefilms were selected using two projectors side-by-side. In any additional cinefilm, only matching frames of the dilated stenoses or newly dilated stenoses were marked for further analysis.
The computer-assisted quantitative analysis system Cardio 500 developed by Kontron Elektronik (Eching, Germany) was used to measure coronary segments and lesions. The selected cineframes were optically magnified (twofold) and digitized into a 512 512 matrix at 8 bit per pixel allowing 256 grey scales. The operator traced the midline in the coronary segment of interest on a digitizer. The computer then automatically defined the vessel borders by an algorithm using the weighted first and second derivative of the pixel density profile perpendicular to the midline. The coronary guiding catheter filmed empty served as a calibration device. The distal tip of each catheter used was cut off and sent to the quantitative coronary angiography core laboratory to measure the true diameter by micrometer.
The coronary tree was divided into 16 segments using branch points as boundaries. For each segment, the mean segment diameter (mm) defined as the mean of all lumen diameter measurements along the segment, minimum lumen diameter (mm), reference diameter (mm), and diameter stenosis (%) were measured. For the dilated segments, a second analysis ('stenosis based') was performed independent of the segment boundaries. For segments or lesions adequately visualized in different, preferably orthogonal projections, the average values of all quantitative coronary angiography parameters were calculated. The mean segment diameter, minimum lumen diameter and reference diameter were scored as '0' mm and diameter stenosis as '100' % for occluded segments. All segments distal to an occlusion were excluded from quantitative coronary angiography analysis. In case of rePTCA or a second PTCA, the measurements immediately before PTCA were used to compare them with the preceeding angiogram, and the post-PTCA measurements were used for comparison with a follow-up angiogram. In patients who underwent CABG during the study, segments distal from the insertion of the graft were analysed if appropriate for quantitative coronary angiography analysis, i.e. good contrast filling whereas the proximal segments were excluded.
Angiographic end-points
Based on the recommendations of de Feyter et al. [25] , two main variables were defined, the mean segment diameter to assess diffuse coronary atherosclerosis, and the minimum lumen diameter to assess focal coronary atherosclerosis. In addition, all analyses were done separately for dilated and non-dilated segments.
The primary angiographic end-point was to compare the per-patient mean between usual care and lovastatin groups after 2 years of mean segment diameter changes for all non-dilated segments.
Secondary angiographic end-points were separated into two groups, (a) dilated compared with non-dilated segments independent of treatment and (b) comparison of treatment groups. All analyses were done on a per-patient basis. (a) Long-term differences in progression between dilated and non-dilated segments between 4 and 24 months were assessed by comparing the minimum lumen diameter of non-dilated and dilated segments independent of the treatment groups in patients without rePTCA. (b) The treatment groups were compared on a perpatient basis for seven secondary end-points; (1) the difference in mean segment diameter changes in dilated segments in patients without rePTCA; (2) the difference in minimum lumen diameter changes in dilated and non-dilated segments after 4 and 24 months; (3) the proportion of patients with restenosis; (4) the proportion of patients classified as progressors; (5) the proportion of patients classified as regressors; (6) the proportion of patients with one or more new lesions, and (7) the proportion of patients with new occlusions. Two definitions of restenosis were used: narrowing of the minimum lumen diameter >0·36 mm (three times the precision of the quantitative coronary angiography system [26] ) and diameter stenosis >50% at the follow-up coronary angiogram. A progressor was a patient with a narrowing of >0·24 mm of the minimum lumen diameter (twice the precision of the quantitative coronary angiography system [26] ) without regression. A patient in whom the minimum lumen diameter widened >0·24 mm in at least one segment, without any progression in another, was classified as a regressor. In case of simultaneous progression and regression or any pro-/ regression in a given patient, the patient was classified as 'no change'. A new lesion was defined as a narrowing of the minimum lumen diameter >0·24 mm or >10% increase in diameter stenosis in a segment without a stenosis >20% at baseline.
Statistical analysis
Assuming a drop-out rate of 20%, using a one-tailed approach with a power of 0·80, a type I error of 0·05, an estimated standard deviation of 0·12 mm for change of mean segment diameter, a sample size of 220 patients was needed to detect the expected difference of 0·07 mm for the primary angiographic end-point. For all continuous variables, the mean, median, standard deviation and 95% confidence interval were calculated. The Student t-test, the Wilcoxon-Mann-Whitney rank sum test, and the chi-square test where appropriate, were used to compare the treatment groups for baseline characteristics as well as for the primary and secondary angiographic end-points. A probability value of 0·05 was considered to be significant. Treatment effects were compared in subgroups of patients using quintiles of the baseline lipid parameters for the primary and secondary angiographic end-points. The SAS statistical package (Version 6.11) were used to perform all analyses [27] .
Results
Study population, baseline characteristics
Of 226 randomized male patients, 199 underwent PTCA at baseline and were finally included in the study. One hundred and eighty-one patients (91%) had their first control coronary angiogram after 6 months and 159 (80%) their final coronary angiogram after 2 years. The reasons for study discontinuation are summarized in Table 2 . The biographical and baseline data of the 226 patients randomized according to treatment allocation are summarized in Table 3 . The treatment groups of the finally included patients were well balanced with respect to baseline characteristics.
Effect of treatment on serum lipid levels
The serum lipid levels of the treatment groups are summarized in Table 4 . According to the study protocol, the lovastatin dosage was increased to 40 mg . day . Total cholesterol and LDL cholesterol decreased by 21% and 29% in lovastatin treated patients, and by 7% and 11% in usual care patients after 2 years, respectively (P<0·001). Over the same period, HDL cholesterol increased by 7% (ns) and triglycerides decreased by 1% (ns) in special care patients. Lipoprotein (a) was not influenced by the treatment and remained constant during the study.
Angiographic results
Five hundred and twenty-one study angiograms and 105 additional coronary angiograms were analysed by quantitative coronary angiography. In total, 1593 different non-dilated coronary segments in each of the three study coronary angiograms were measured by quantitative coronary angiography. 10·2 segments per patient in 1·87 projections per segment were analysed yielding a total of 8940 measurements of non-dilated segments.
One thousand and ninety three quantitative coronary angiography measurements in dilated segments with a mean of 2·3 projections were analysed. Two hundred and twenty nine different target lesions (mean 1·32 per patient) were dilated at baseline and analysed between baseline and 4 months. One hundred and forty-two of these target lesions (mean 1·25 per patient), excluding patients with rePTCA, were measured between baseline, 4 months and 2 years of follow-up, respectively.
Continuous variables Primary angiographic end-point
The mean segment diameters of non-dilated segments at baseline and follow-up and the changes in mean segment diameters are summarized in Table 5 by treatment groups. After 2 years of treatment with lovastatin, a significant treatment effect was not apparent: the mean P-value non significant for all baseline characteristics.
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difference between the groups in terms of mean segment diameter changes were 0·03 mm with a 95% CI of 0·06 to 0·12 mm.
Secondary angiographic end-points
Similar results were obtained in the changes in minimum lumen diameter in non-dilated segments. The minimum lumen diameter decreased by 0·04 0·24 mm in usual care patients and by 0·22 0·22 mm in special care patients after 2 years, respectively (P=0·28, one-sided).
The lovastatin-related difference between the groups of 0·02 mm (95% CI 0·05 to 0·09 mm) was not significant after 2 years. The effect of lovastatin was not significantly different in relation to baseline serum lipid levels of total cholesterol, LDL-and HDL cholesterol, and Lp (a) (ns). A correlation between baseline lipid levels and angiographic outcome was not observed (ns). Table 6 summarizes the changes in mean segment diameter and minimum lumen diameter of dilated segments.
Dilated lesions Mean segment diameter changes and minimum lumen diameter changes
The lovastatin-related treatment effect on mean segment diameter over 2 years is summarized in Fig. 1 .
The focal atherosclerotic changes assessed by using the minimum lumen diameter as a target variable was not significantly influenced by lovastatin. The differences in minimum lumen diameter between the groups were 0·08 mm after 4 months (CI 0·07 to 0·23 mm, P=0·13), 0·08 mm between 4 and 24 months (CI 0·05 to 0·21 mm, P=0·20) and 0·08 mm after 2 years (CI 0·12 to 0·28 mm, P=0·22), respectively. Figure 2 illustrates the mean segment diameter and minimum lumen diameter in 114 patients with a rePTCA during study follow-up. Within 4 months of PTCA the diameter decreased, but in the following 20 months, a marked increase in diameter was observed, independent of treatment group.
Restenosis
The initial gain by PTCA in minimum lumen diameter (comparing the measurements before and immediately after PTCA) was identical in both groups (usual care: 0·66 0·40 mm, special care: 0·67 0·47 mm; P=0·27). With regard to net gain (defined as minimum lumen diameter of the follow-up cinefilm minus minimum lumen diameter before PTCA), no lovastatin effect was observed (usual care: 0·45 0·54 mm, special care: 0·48 0·55 mm; P=0·36).
Restenosis (defined as a decrease in minimum lumen diameter >0·36 mm at the follow-up coronary angiogram) was apparent in 32·2% (n=44) and 33·6% (n=36 lesions) of dilated lesions in the usual care and special care groups, respectively. On a patient-based analysis, 30·5% (n=29) of usual care patients and 26·6% (n=21) of lovastatin treated patients had restenosis (P=0·28). Similar findings were obtained using >50% diameter stenosis at follow-up angiogram as a definition of restenosis. A restenosis rate of 34·1% (n=43) in usual care and 29·4% (n=32) in special care was observed for per-lesion analysis. On a per-patient basis, 28·4% (n=27) of usual care and 22·2% (n=18) of special care patients had restenosis (P=0·17), respectively.
Differences in progression between dilated and non-dilated segments
In a subgroup of 114 patients without a second intervention during follow-up, the change in minimum lumen diameter between 4 and 24 months was assessed for differences between dilated lesions and non-dilated segments (Fig. 3) .
Categorical variables Proportion of patients with progression/regression
19·8% of usual care and 20·5% of special care patients were classified as progressors (ns). Regression without 
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any progression was observed in 12·8% of the usual care group and in 20·5% of the lovastatin-treated group, respectively (ns). 66·3% of the usual care patients and 57·5% of the special care patients were classified as 'no change' patients (ns).
New lesions and occlusions
Of the 1593 non-dilated segments, 634 had no stenosis >20% at baseline angiogram. In 38 (10·7%) segments of the usual care patients and 32 (11·5%) segments of the special care patients, a new lesion was apparent at the 2-year follow-up angiogram (ns). On a per-patient basis, 27 (31·4%) of usual care patients and 22 (30·1%) of special care patients developed a new lesion within 2 years (ns). Occlusions in dilated segments occurred in five (5%) usual care patients and three (4%) special care patients (ns). In non-dilated segments, an occlusion was observed in two (2%) usual care and in one (1%) special care patients (ns).
Critical events
The critical events are listed in Table 7 . Eight patients in the usual care group and four in the lovastatin group needed CABG (reduction 50%, P=ns). Four of the eight patients in the usual care group had a dissection in the target lesion at baseline PTCA requiring CABG; the remaining four patients had restenosis or progression of coronary artery disease requiring CABG. In the lovastatin group, the reason for CABG was restenosis after 8 to 12 months in three patients and progression of coronary artery disease in one patient. During follow-up, three usual care patients had a second and one patient a third rePTCA, in special care eight patients had a second and two a third rePTCA, respectively (P=0·02).
A second PTCA (PTCA of a stenosis other than the target lesion) during follow-up was performed in 16 (16·5%) usual care patients and 11 (13·1%) special care patients (ns). Four usual care patients needed a second rePTCA, and one patient a second and third rePTCA. In special care, rePTCA was performed in six patients, one of whom needed a second rePTCA.
After 2 years of treatment, 65·2% of the special care and 54·9% of the usual care patients were without an event (ns). 96·4% of the lovastatin treated patients and 89·4% of the usual care patients did not have a myocardial infarction, a bypass, or die (P=0·04, two-sided).
Discussion
CLAPT is the first prospective, randomized angiographic secondary prevention trial in patients with PTCA as primary treatment to assess the effect of a 2-year treatment with lovastatin on progression and regression of coronary artery disease. The unique CLAPT design in which patients with PTCA as primary treatment allowed analysis of the effect of lovastatin in both, non-dilated and dilated lesions. The results will be discussed separately because atherosclerosis in nondilated lesions and neointimal proliferation induced by PTCA in dilated lesions have a different underlying pathophysiology.
Previous studies
Non-dilated segments To date, the results of six angiographic studies using a HMG-CoA reductase inhibitor as monotherapy have been reported [2, 4, 5, 11, 12, 14] . The Monitored Atherosclerosis Regression Study (MARS) and the Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) used lovastatin, the Multicenter Antiatheroma Study (MAAS) and the Multicenter Coronary Intervention Study (CIS) used simvastatin. These studies included patients with coronary artery disease documented angiographically and excluded patients with planned PTCA [2, 4, 5, 11, 12] . Only REGRESS (pravastatin treatment) included patients with primary PTCA as one of three randomization arms but reported angiographic , n=62) , the minimum lumen diameter of dilated lesions increased by 0·05 0·34 mm, whereas in non-dilated lesions, it decreased by 0·03 0·21 mm (P=0·04, two-sided). The minimum lumen diameter of dilated lesions increased in lovastatin-treated patients (untinted bars, n=52) by 0·08 0·24 mm and non-dilated segments by 0·01 0·21 mm (P=0·03, two-sided). 
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results only for non-dilated segments [14] . The angiographic results in relation to the lipid lowering effect are summarized in Table 8 .
MARS reported the mean change in minimum lumen diameter as a secondary end-point [2] . CCAIT (Canadian Coronary Atherosclerosis Intervention Trial) defined the mean change in minimum lumen diameter as the primary end-point [4] . CIS used two primary end-points, mean change of minimum lumen diameter and a visually based global change score [5] . MAAS and REGRESS defined a combined primary angiographic end-point, the change in mean lumen diameter for diffuse atherosclerosis and the change in minimum lumen diameter for focal atherosclerosis. In contrast to the other trials, however, MAAS had a 4-year follow-up [11, 14] . To date, REGRESS is the only prospective trial of patients with PTCA as the primary treatment in one of three randomization blocks [14] . The angiographic findings in CLAPT are consistent with these trials (Table 8) but CLAPT failed to demonstrate a positive lovastatin-related treatment effect on progression of non-dilated segments, with less pronounced absolute differences between the groups compared to the discussed five angiographic trials. The lack of efficacy in CLAPT may be related to (1) the effective dietary treatment with a pronounced lipid reduction in usual care patients, (2) differences in study population, and (3) the smaller study population.
1. Dietary treatment in the usual care group reduced total and LDL-cholesterol in CLAPT up to fivefold, as in the trials discussed. This good response to diet may be the main reason for the better angiographic outcome in usual care patients. The reduction in minimum lumen diameter or mean segment diameter in non-dilated segments and the proportion of usual care patients classified as progressors was smallest in CLAPT. Similarly, the lovastatin-treated patients had the lowest (almost no) progression in non-dilated segments of the various trials, but the lovastatin-related effect was not strong enough to show a significant difference between the groups [2, 4, 11, 12] . 2. In the previous studies, the primary and secondary end-points included analysis of all segments, whereas in CLAPT the primary end-point was based on analysis of non-dilated segments. Exclusion of dilated segments seems necessary in CLAPT because dilation induces a response in the vessel wall, with initial elastic recoil, subsequent intimal proliferation, and further remodelling within the first 4 to 6 months [28] . This is different from progression in non-dilated segments. Therefore, a separate analysis of non-dilated segments in CLAPT might bias our results with selection of the more 'stable' lesions (and PTCA of the more unstable lesions) which may result in less progression and smaller treatment effects of lipid-lowering in non-dilated segments [2, 4, 11, 12] . Only the angiographic findings in the PTCA treatment arm of REGRESS are based on analysis of non-dilated segments, with similar results for the change in mean segment diameter. But the difference in change in minimum lumen diameter between the groups in REGRESS was four times higher than in CLAPT. Since no further angiographic findings or details are published for the PTCA treatment arm of REGRESS, we have to speculate whether differences in lipid reduction, in the selection of the dilated target lesion or number and severity of additional lesions may be responsible for this observation [14] . 3. In CLAPT the overall direction of findings were consistent with the other five trials, without reaching statistical significance. This may be related to the smaller number of patients with a 2-year angiographic follow-up with less statistical power [2, 4, 11, 12, 14] .
Restenosis and dilated lesions
Two trials investigated whether lovastatin would prevent restenosis after PTCA. Sahni et al. [18] randomized 157 patients to lovastatin and conventional therapy after PTCA. Fifty lovastatin-treated patients and 19 control patients had an angiographic follow-up study after 4 months. The restenosis rate defined as diameter stenosis >50% at the follow-up angiogram was 12% in treated patients and 44% in control (P<0·001). The main limitation of this study is the incomplete angiographic follow-up of only 51% of the patients [18] . The Lovastatin Restenosis trial (LRT), a prospective, randomized placebo-controlled trial, included 404 patients, with angiographic restudy in 91% of the patients. Treatment with lovastatin at a high dosage (80 mg . day 1 ) was started 7 to 10 days prior to PTCA. After 6 months of treatment, no significant difference in restenosis rate was observed between the groups (46% vs 44%) [19] . Similarly, the Fluvastatin Angioplasty Restenosis (FLARE) and Pravastatin on Angiographic Restenosis After Coronary Balloon Angioplasty (PREDICT) trials failed to demonstrate a reduction of restenosis rate [29, 30] . Consistent with these findings, 4 weeks of pre-treatment with lovastatin did not influence the restenosis rate in CLAPT. Again, the promising results of experimental data with an antiproliferative effect of lovastatin in animals after angioplasty is not effective enough to reduce restenosis after PTCA in humans, probably because of a difference in serum concentrations or differences in species [16, 17] . The vessel response after PTCA has been intensively investigated by quantitative coronary angiography. Within hours of PTCA, elastic recoil leads to renarrowing of the vessel lumen diameter [28] . Further reduction in vessel diameter by intimal hyperplasia and remodelling occurs within weeks to months [28] . Restenosis trials using quantitative coronary angiography give information about the 'late' angiographic outcome within a 6-month follow-up, but there is a lack of information about the long-term angiographic outcome within 2 years based on a prospective, randomized study [31, 32, 33, 34] . 
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Similar to the findings of restenosis trials, the minimum lumen diameter and the mean segment diameter of dilated lesions decreased (as expected) in the first 4 months after PTCA [30, 31, 33, 34, 35] . But in the following 20 months, both parameters increased, again with an improvement in the 2 year angiographic outcome comparable to the result immediately after PTCA (Fig. 2) . Kimura et al. reported a similar observation after stent implantation with an increase in minimum lumen diameter in follow-up angiograms after 3 years compared to the first angiographic control after 6 months [36] . Ormiston et al. reported lesion regression at the dilated site 5 years after PTCA (decrease in stenosis severity from 36·3% to 29·6%, P<0·001) in an angiographic study of 124 consecutive patients with a late angiographic follow-up in 84 patients [37] . These observations suggest that restenosis may be a biphasic process, with an 'anabolic' phase characterized by neointimal proliferation within the first 6 months and a 'catabolic' phase with shrinkage of neointimal proliferation over the subsequent months. The increase in minimum lumen diameter and mean segment diameter might be related to a reduction in extracellular matrix over time which could be modified by lipid lowering or the modulating effect of lovastatin via cytokines or growth factors.
We also demonstrated that regression occurred more often in dilated segments compared to progression in non-dilated segments within a patient between 4 and 24 months (Fig. 3) . This suggests that atherosclerosis of non-dilated segments has a different pathophysiological mechanism from dilated lesions. Therefore, long-term angiographic outcome justifies conservative treatment in patients with borderline stenosis at the 6 month follow-up angiogram.
Critical events
The number of critical events was smaller in the lovastatin-treated group. Since CLAPT was designed as an angiographic secondary prevention trial, the sample size was too small to expect a statistical difference. However, the results of the 4S Study demonstrated the clinical importance of lipid lowering in secondary prevention of coronary artery disease with a 42% reduction of coronary deaths [38] .
Limitations of the study CLAPT was designed to assess the effect of lovastatin treatment on both non-dilated and dilated lesions in patients with PTCA. The sample size calculation of the trial was based on two assumptions, (1) that patients scheduled for PTCA represent a population at higher risk for progression than patients with angiographically documented coronary artery disease not requiring intervention and therefore, (2) that lovastatin treatment had an effect on non-dilated lesions in the upper range of the reported trials. However, the observed rate of progression of non-dilated segments was less than in other studies and the statistical power of CLAPT was not sufficient to demonstrate a difference between the groups. The low progression rate in non-dilated segments may be due to the study design, which may have targeted PTCA to those stenosis that might have shown a higher rate of spontaneous progression if they had not been dilated. Furthermore, the open study design with different clinical follow-up (outpatient clinic visits in special care and telephone contact in usual care) could have influenced the clinical decision for rePTCA, second-PTCA or CABG. Concerning quantitative coronary angiography analysis, blinding of the angiograms will have assured an unbiased analysis of the angiographic end-points. All conclusions are restricted to men in whom PTCA was indicated. An extrapolation of the results to women seems to be difficult. The exclusion of women was necessary because it appeared impossible to include enough women in a reasonable time to allow statistical analysis.
Conclusions
In men who undergo PTCA for clinical reasons, with moderately elevated serum cholesterol levels, treatment with lovastatin reduced progression of dilated lesions. Independent of treatment allocation, the dilated lesions showed regression compared to progression of non-dilated segments after 2 years.
Four weeks of pre-treatment with lovastatin did not influence restenosis rate. Lovastatin did not have a statistically significant effect on non-dilated segments and the number of new lesions.
